Placebo: Participants will receive placebo matching to KN3835.
Study summary
The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Key Inclusion Criteria:
* Has no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration or study required evaluations.
* If female, be of non-childbearing potential or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective contraception when with a male partner for the duration of the study and for 28 days after treatment.
* Be willing and able to comply with all protocol required visits and assessments.
Key Exclusion Criteria:
* Has any musculoskeletal, neurosensory, other neurological or related disorder that affects the participant's use of his/her feet and/or would impair his/her completion of study assessments as determined by the investigator either due to the disorder or due to pain.
* Has any significant medical condition(s), which in the investigator's opinion would make the participant unsuitable for enrollment in the study.
* Has previously participated in clinical studies of KN3835 for plantar fasciitis, plantar fibromatosis, or HMT.
Note: Other inclusion/exclusion criteria may apply.
Primary outcome measure(s)
Change From Baseline to Day 57 in Flexion Contracture as Measured by Goniometer — Baseline, Day 57
Trial sites (7)
Facility
City
Region
Status
Keenova Site-009
Corona
California
Recruiting
Keenova Site-008
Tarzana
California
Recruiting
Keenova Site-004
Pinellas Park
Florida
Recruiting
Keenova Site-007
Sweetwater
Florida
Recruiting
Keenova Site-003
Bedford
Texas
Recruiting
Keenova Site-002
McAllen
Texas
Recruiting
Keenova Site-006
Salt Lake City
Utah
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.